Compound 2339
Identifiers
- Canonical SMILES:
COc1cc(ccc1NC(=O)[C@H]1N[C@H](CC(C)(C)C)[C@@]2([C@@H]1c1cccc(Cl)c1F)C(=O)Nc1cc(Cl)sc21)C(N)=O
- IUPAC name:
(2R,3S,4S,5S)-N-(4-carbamoyl-2-methoxyphenyl)-2'-chloro-4-(3-chloro-2-fluorophenyl)-2-(2,2-dimethylpropyl)-5'-oxo-4',5'-dihydrospiro[pyrrolidine-3,6'-thieno[3,2-b]pyrrole]-5-carboxamide
- InChi:
InChI=1S/C29H29Cl2FN4O4S/c1-28(2,3)12-19-29(24-17(35-27(29)39)11-20(31)41-24)21(14-6-5-7-15(30)22(14)32)23(36-19)26(38)34-16-9-8-13(25(33)37)10-18(16)40-4/h5-11,19,21,23,36H,12H2,1-4H3,(H2,33,37)(H,34,38)(H,35,39)/t19-,21-,23+,29+/m1/s1
- InChiKey:
UOVSZRTTWLJPHE-RPMQLHGRSA-N
External links
![]() 66764524 |
![]() CHEMBL3109037 |
20W |
External search
![]() |
![]() |
![]() |
![]() |
![]() |
Bibliography (1)
Publication | Name |
---|---|
Vassilev L. T.. . In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 Science. | 19 |
Pharmacological data
Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|
1 | 1 | 0 | 0 |
Targets
PPI family | Best activity | Diseases | MMoA |
---|---|---|---|
MDM2-Like / P53 | 6.75 | cancer | Inhibition |
Physicochemical filters
Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
---|---|---|---|---|
Compliance | ||||
MW | 618.13 g/mol | |||
HBA | 8 | |||
HBD | 5 | |||
HBA + HBD | 13 | |||
AlogP | 5.46 | |||
TPSA | 127.13 | |||
RB | 7 |
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|---|
1 | 1 | 1 | 0 | 0 |
Pharmacological data
Bibliography | Name | Target | Competition | Assay type | Assay name | Cell line | Activity type | Activity |
---|---|---|---|---|---|---|---|---|
10.1126/science.1092472 | 19 | MDM2 Q00987 |
P53 P04637 |
Biochemical assay | HTRF | pIC50 (half maximal inhibitory concentration, -log10) | 6.75 | |
10.1126/science.1092472 | 19 | MDM2 Q00987 |
P53 P04637 |
Cellular assay | MTT-assay | SJSA-1 + HCT116 + RKO | pIC50 (half maximal inhibitory concentration, -log10) | 6.07 |
Ta | Structure | Name | Drugbank ID |
---|---|---|---|
0.5922 | SAR-405838 | DB12541 | |
0.5758 | Idasanutlin | DB12325 | |
0.5502 | Milademetan | DB15257 | |
0.4167 | 3-{6-[(8-HYDROXY-QUINOLINE-2-CARBONYL)-AMINO]-2-THIOPHEN-2-YL-HEXANOYLAMINO}-4-OXO-BUTYRI ACID | DB07916 | |
0.4130 | Degarelix | DB06699 | |
0.4054 | OPC-51803 | DB05838 | |
0.4025 | (S)-2-CHLORO-N-(1-(2-(2-HYDROXYETHYLAMINO)-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL)-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE | DB07792 | |
0.4006 | 2-CHLORO-N-[(3R)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE | DB07066 | |
0.4000 | Satavaptan | DB14923 | |
0.3987 | MK-3207 | DB12424 | |
0.3970 | OPC-14523 | DB05422 | |
0.3955 | N-[3-[4-(3-aminopropyl)piperazin-1-yl]propyl]-3-[(2-thiophen-2-ylacetyl)amino]-5-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybenzamide | DB03524 | |
0.3953 | 5-CHLORO-THIOPHENE-2-CARBOXYLIC ACID ((3S,4S)-4-FLUORO- 1-{[2-FLUORO-4-(2-OXO-2H-PYRIDIN-1-YL)-PHENYLCARBAMOYL]-METHYL}-PYRROLIDIN-3-YL)-AMIDE | DB08143 | |
0.3918 | 5-chloro-N-[(3R)-1-(2-{[2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl]amino}-2-oxoethyl)pyrrolidin-3-yl]thiophene-2-carboxamide | DB07872 | |
0.3873 | Labradimil | DB06549 |